MiMedx Group Inc Stock Nasdaq
Equities
US6024961012
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.335 USD | +126.25% | -52.57% | -76.61% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Financials (USD)
Sales 2024 * | 357M | Sales 2025 * | 403M | Capitalization | 930M |
---|---|---|---|---|---|
Net income 2024 * | 43M | Net income 2025 * | 56M | EV / Sales 2024 * | 2.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.31 x |
P/E ratio 2024 * |
20.6
x | P/E ratio 2025 * |
16.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.24% |
Latest transcript on MiMedx Group Inc
Managers | Title | Age | Since |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 23-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 23-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 20-07-01 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 21-03-07 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-18 |
1st Jan change | Capi. | |
---|---|---|
-22.12% | 125M | |
+1.90% | 58.14M | |
-2.40% | 50.15M |